Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (251-260 of 487) with videos related to

Pageof 49
Sort By:
Journal of Computer Assisted Tomography|December 1, 2017
Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver TumorsPayel Ghosh, Adam G Chandler, Brian P Hobbs, et al.
Journal of Hematology & Oncology|January 16, 2014
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion proteinVivek Subbiah, Shannon N Westin, Kai Wang, et al.
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Cell Reports. Medicine|December 20, 2023
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancersMirella Nardo, Mohamed A Gouda, Blessie E Nelson, et al.
Nature Medicine|May 20, 2025
Cancer treatment paradigms in the precision medicine eraVivek Subbiah, Giuseppe Curigliano, Jason K Sicklick, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastasesVivek Subbiah, Jenny Berry, Michael Roxas, et al.
JAMA Network Open|November 3, 2022
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology AssessmentSreeram V Ramagopalan, Sanjay Popat, Alind Gupta, et al.
British Journal of Cancer|January 10, 2018
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaRachna T Shroff, Mark Yarchoan, Ashley O'Connor, et al.
Healthcare (Basel, Switzerland)|December 17, 2024
Understanding the Landscape of Cancer Care in Europe: Evaluating Clinical and Comprehensive Cancer CentersDenis Horgan, Marc Van den Bulcke, Núria Malats, et al.
CA: a Cancer Journal for Clinicians|January 4, 2024
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidanceRaffaella Casolino, Philip A Beer, Debyani Chakravarty, et al.
Pageof 49

Showing results (251-260 of 487) with videos related to

Sort By:
Pageof 49
Journal of Computer Assisted Tomography|December 1, 2017
Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver TumorsPayel Ghosh, Adam G Chandler, Brian P Hobbs, et al.
Journal of Hematology & Oncology|January 16, 2014
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion proteinVivek Subbiah, Shannon N Westin, Kai Wang, et al.
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Cell Reports. Medicine|December 20, 2023
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancersMirella Nardo, Mohamed A Gouda, Blessie E Nelson, et al.
Nature Medicine|May 20, 2025
Cancer treatment paradigms in the precision medicine eraVivek Subbiah, Giuseppe Curigliano, Jason K Sicklick, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastasesVivek Subbiah, Jenny Berry, Michael Roxas, et al.
JAMA Network Open|November 3, 2022
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology AssessmentSreeram V Ramagopalan, Sanjay Popat, Alind Gupta, et al.
British Journal of Cancer|January 10, 2018
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaRachna T Shroff, Mark Yarchoan, Ashley O'Connor, et al.
Healthcare (Basel, Switzerland)|December 17, 2024
Understanding the Landscape of Cancer Care in Europe: Evaluating Clinical and Comprehensive Cancer CentersDenis Horgan, Marc Van den Bulcke, Núria Malats, et al.
CA: a Cancer Journal for Clinicians|January 4, 2024
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidanceRaffaella Casolino, Philip A Beer, Debyani Chakravarty, et al.
Pageof 49